DOCSLIB.ORG

Korea Morning Focus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

September 20, 2019 Korea Morning Focus No English report summaries this morning Major Indices Close Chg Chg (%) KOSPI 2,080.35 9.62 0.46 KOSPI 200 274.92 1.86 0.68 KOSDAQ 645.71 0.59 0.09 Turnover ('000 shares, Wbn) Volume Value KOSPI 483,575 4,797 KOSPI 200 68,123 3,095 KOSDAQ 850,737 4,009 Market Cap (Wbn) Value KOSPI 1,390,938 KOSDAQ 226,266 KOSPI Turnover (Wbn) Buy Sell Net Foreign 1,460 1,242 218 Institutional 966 1,065 -99 Retail 2,338 2,439 -101 KOSDAQ Turnover (Wbn) Buy Sell Net Foreign 412 380 32 Institutional 151 161 -10 Retail 3,419 3,441 -22 Program Buy / Sell (Wbn) Buy Sell Net KOSPI 1,013 947 66 KOSDAQ 353 353 0 Advances & Declines Advances Declines Unchanged KOSPI 340 473 81 KOSDAQ 684 510 112 KOSPI Top 5 Most Active Stocks by Value (Wbn) Price (W) Chg (W) Value Samsung Electronics 49,150 1,450 741 Hynix 82,700 2,500 235 KODEX Leverage 12,350 155 232 KODEX Kosdaq150 7,500 -10 203 Leverage KODEX KOSDAQ150 8,505 5 178 INVERSE KOSDAQ Top 5 Most Active Stocks by Value (Wbn) Price (W) Chg (W) Value RANIX 9,330 1,240 170 Eagle Vet 9,400 -1,200 142 Kukil Paper 5,210 170 142 Mega MD 3,230 515 118 KRTNet Corporation 4,425 255 87 Note: As of September 19, 2019 This document is a summary of a report prepared by Mirae Asset Daewoo Co., Ltd. (“Mirae Asset Daewoo”) and published on our website. Please review the compliance notices contained in the original report. Information and opinions contained herein have been compiled in good faith from sources deemed to be reliable. However, the information has not been independently verified. Mirae Asset Daewoo makes no guarantee, representation or warranty, express or implied, as to the fairness, accuracy or completeness of the information and opinions contained in this document. Mirae Asset Daewoo accepts no responsibility or liability whatsoever for any loss arising from the use of this document or its contents or otherwise arising in connection therewith. Information and opinions contained herein are subject to change without notice. This document is for informational purposes only. It is not and should not be construed as an offer or solicitation of an offer to purchase or sell any securities or other financial instruments. This document may not be reproduced, further distributed or published in whole or in part for any purpose. Mirae Asset Daewoo Research Key Universe Valuations September 20, 2019 ※All data as of close September 18, 2019, unless otherwise noted. 19F Earnings growth Mkt Cap Price P/E (x) P/B (x) ROE (%) Ticker Company Div Yield OP EPS (Wbn) (W) (%) 19F 20F 19F 20F 19F 20F 19F 20F 19F 20F 005930 Samsung Electronics 293,415 49,150 2.9 -53.4 23.9 -46.6 21.4 15.3 12.6 1.3 1.2 8.8 10.0 000660 SK Hynix 60,206 82,700 1.8 -85.3 102.4 -84.1 94.0 24.4 12.6 1.2 1.1 5.2 9.5 005380 Hyundai Motor 27,563 129,000 3.1 67.7 4.7 142.3 10.8 9.9 9.0 0.5 0.5 5.2 5.5 035420 NAVER 25,958 157,500 0.2 -23.3 105.7 -50.8 169.4 81.4 30.2 3.8 3.4 5.9 14.5 012330 Hyundai Mobis 23,398 245,500 1.6 10.3 7.8 25.4 8.8 10.1 9.3 0.7 0.7 7.4 7.4 051910 LG Chem 23,119 327,500 1.8 -35.9 64.2 -45.2 95.2 31.7 16.3 1.4 1.3 4.7 8.7 068270 Celltrion 21,625 168,500 - - - - 0.0 0.0 005490 POSCO 20,358 233,500 4.3 -21.1 -1.8 55.3 -0.7 7.8 7.8 0.4 0.4 5.9 5.7 055550 Shinhan Financial Group 20,035 42,250 14.3 5.4 11.3 0.9 5.7 5.7 0.5 0.5 9.3 8.6 051900 LG H&H 19,632 1,257,000 0.9 12.8 9.7 16.5 10.7 24.7 22.3 5.4 4.6 20.3 19.1 017670 SK Telecom 19,217 238,000 4.2 11.4 3.3 -58.6 71.4 14.8 8.7 0.8 0.7 5.7 9.3 105560 KB Financial Group 17,937 42,900 10.3 4.1 12.6 3.2 5.2 5.0 0.5 0.4 9.3 8.9 000270 Kia Motors 17,654 43,550 1.8 20.5 19.7 54.5 16.7 9.9 8.5 0.6 0.6 6.3 7.0 028260 Samsung C&T 17,300 91,200 2.2 -16.8 41.4 -39.5 16.8 16.8 14.4 0.6 0.6 4.2 4.1 015760 KEPCO 16,306 25,400 - 305.3 - - - 26.6 0.2 0.2 - 0.9 006400 Samsung SDI 16,263 236,500 0.4 22.3 40.8 14.1 34.5 20.8 15.5 1.3 1.2 6.4 8.0 096770 SK Innovation 15,627 169,000 4.7 -37.5 28.9 -60.6 85.6 24.4 13.1 0.8 0.8 3.6 6.5 018260 Samsung SDS 15,398 199,000 1.3 13.6 15.8 13.2 15.8 21.6 18.7 2.3 2.1 11.3 12.0 034730 SK Holdings 14,776 210,000 2.4 3.5 23.6 -50.2 14.0 13.3 11.6 0.8 0.8 6.5 6.9 032830 Samsung Life 14,380 71,900 - - - - 0.0 0.0 033780 KT&G 14,072 102,500 4.1 12.8 5.6 17.5 5.1 13.3 12.6 1.6 1.5 12.7 12.6 003550 LG Corp. 12,252 71,000 3.2 17.2 15.4 5.5 15.6 6.3 5.5 0.6 0.6 10.5 11.1 036570 NCsoft 11,526 525,000 1.2 4.9 73.6 31.4 51.5 21.0 13.8 3.6 2.9 21.3 26.5 035720 Kakao 11,355 135,500 0.1 184.9 132.6 205.6 127.5 72.3 31.8 2.1 2.0 3.0 6.5 010950 S-Oil 11,225 99,700 1.3 10.0 148.5 39.0 265.3 32.4 8.9 1.7 1.5 5.4 17.7 000810 Samsung F&M 10,896 230,000 - - - - 0.0 0.0 066570 LG Electronics 10,670 65,200 1.2 -11.8 30.9 -20.9 81.5 12.0 6.6 0.8 0.7 6.6 11.1 086790 Hana Financial Group 10,644 35,450 11.5 6.2 9.6 8.5 4.3 4.0 0.4 0.3 9.0 8.9 009540 KSOE 8,599 121,500 - 215.7 - 27.2 210.7 165.6 0.7 0.7 0.3 0.4 011170 Lotte Chemical 8,535 249,000 4.2 -35.3 21.0 -39.4 30.8 8.9 6.8 0.6 0.6 7.3 9.0 010130 Korea Zinc 8,208 435,000 2.5 14.1 2.3 26.3 -2.0 12.3 12.6 1.2 1.1 10.2 9.3 251270 Netmarble 8,204 95,700 16.8 50.4 24.2 35.1 34.6 25.6 1.7 1.6 5.3 6.7 090430 AmorePacific 8,097 138,500 0.8 -15.7 30.9 -9.8 31.4 27.0 20.6 2.1 1.9 6.6 8.1 024110 Industrial Bank of Korea 7,589 13,200 6.0 3.0 3.9 2.0 4.8 4.7 0.4 0.4 8.5 8.1 009150 Samsung Electro-Mechanics 7,544 101,000 1.1 -39.9 36.8 -3.0 -7.6 12.3 13.3 1.4 1.3 12.4 10.3 091990 Celltrion Healthcare 7,268 50,500 - 214.5 745.0 180.7 75.2 26.8 4.0 3.6 5.7 14.8 030200 KT 7,194 27,550 4.0 9.5 1.0 18.2 5.3 8.8 8.4 0.5 0.5 6.0 6.0 018880 Hanon Systems 6,512 12,200 - - - - 0.0 0.0 032640 LG Uplus 5,872 13,450 4.8 -13.0 8.7 -18.0 12.3 14.9 13.2 0.8 0.8 5.7 6.2 Hyundai Heavy Industries 267250 5,798 356,000 5.2 78.7 2.1 154.0 4.5 8.5 8.1 0.7 0.6 8.6 8.5 Holdings 086280 Hyundai Glovis 5,606 149,500 2.2 13.5 4.6 23.2 21.9 10.4 8.5 1.2 1.1 11.9 13.1 004020 Hyundai Steel 5,351 40,100 1.9 6.1 22.5 53.1 31.9 8.8 6.6 0.3 0.3 3.5 4.3 034220 LG Display 5,260 14,700 - - - - - 28.3 0.4 0.4 - 1.4 000720 Hyundai E&C 5,217 46,850 1.1 22.4 10.8 49.0 7.3 9.2 8.6 0.8 0.7 8.9 8.9 010140 Samsung Heavy Industries 5,185 8,230 - - - - - 33.1 0.7 0.7 - 2.4 071050 Korea Investment Holdings 4,296 77,100 - - - - 0.0 0.0 047810 Korea Aerospace 4,011 41,150 0.5 72.1 -6.3 265.3 -18.9 19.2 23.7 3.3 3.0 18.9 13.3 271560 Orion 3,918 99,100 0.6 5.1 9.8 42.5 12.5 19.7 17.5 2.4 2.2 13.2 13.1 029780 Samsung Card 3,916 33,800 -16.3 3.1 2.8 4.1 11.0 10.6 0.6 0.5 1.5 1.5 004990 LOTTE Corporation 3,882 37,000 2.2 91.0 11.9 198.2 20.3 7.1 5.9 0.4 0.4 7.5 8.3 Source: Mirae Asset Daewoo Research Mirae Asset Daewoo Research Market Data September 20, 2019 ※All data as of close September 19, 2019, unless otherwise noted.
Recommended publications
  • Cj Enm(035760

    Cj Enm(035760

    August 9, 2018 Result Comment CJ ENM (035760 KS) Decent performance 2Q consolidated operating profit in line at W79.2bn BUY (re-initiate) 3Q consolidated operating profit estimated at W86bn; earnings to stay solid Price (Aug. 8) W236,200 Target Price W270,000 Re-initiate coverage on CJ ENM with a BUY rating and a target price of % variance 14.3% W270,000 HeeJin Park ☎ (82-2) 3772-1562 2Q consolidated operating profit in line at W79.2bn [email protected] CJ ENM posted its first results after the merger on July 1. Consolidated operating profit came in at W79.2bn in 2Q, meeting our forecast of W79.3bn. SeJong Hong ☎ (82-2) 3772-1584 The E&M division delivered solid earnings with sales up 9.2% YoY and operating [email protected] profit up 25% YoY. Broadcasting exceeded expectations with operating profit increasing 22% YoY to W29.2bn. Ad sales growth of 10.2 YoY also turned out better than expected. Music and cinema showed mixed results. The music division KOSPI 2,301.45p posted sales of W66.5bn (+41.1% YoY) and operating profit of W4.2bn (+114% KOSDAQ 783.81p YoY) on strengthening IP (intellectual property) business. By contrast, the Market Cap. W5,179.0bn/ US4,543.0mn cinema/performance division remained in the red with an operating loss of Par Value W5,000 W3.9bn due to stagnant growth of moviegoers and weak line-up. The commerce division (CJ O shopping) registered standalone operating profit of W40.3bn and Outstanding Shares 21.9mn consolidated W33.9bn.
  • FTSE Korea 30/18 Capped

    FTSE Korea 30/18 Capped

    2 FTSE Russell Publications 19 August 2021 FTSE Korea 30/18 Capped Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) Alteogen 0.19 KOREA Hyundai Engineering & Construction 0.35 KOREA NH Investment & Securities 0.14 KOREA AmoreG 0.15 KOREA Hyundai Glovis 0.32 KOREA NHN 0.07 KOREA Amorepacific Corp 0.65 KOREA Hyundai Heavy Industries 0.29 KOREA Nong Shim 0.08 KOREA Amorepacific Pfd. 0.08 KOREA Hyundai Marine & Fire Insurance 0.13 KOREA OCI 0.17 KOREA BGF Retail 0.09 KOREA Hyundai Merchant Marine 1.02 KOREA Orion 0.21 KOREA BNK Financial Group 0.18 KOREA Hyundai Mipo Dockyard 0.15 KOREA Ottogi 0.06 KOREA Celltrion Healthcare 0.68 KOREA Hyundai Mobis 1.53 KOREA Paradise 0.07 KOREA Celltrion Inc 2.29 KOREA Hyundai Motor 2.74 KOREA Posco 1.85 KOREA Celltrion Pharm 0.24 KOREA Hyundai Motor 2nd Pfd. 0.33 KOREA Posco Chemical 0.32 KOREA Cheil Worldwide 0.14 KOREA Hyundai Motor Pfd. 0.21 KOREA Posco International 0.09 KOREA CJ Cheiljedang 0.3 KOREA Hyundai Steel 0.33 KOREA S1 Corporation 0.13 KOREA CJ CheilJedang Pfd. 0.02 KOREA Hyundai Wia 0.13 KOREA Samsung Biologics 0.92 KOREA CJ Corp 0.11 KOREA Industrial Bank of Korea 0.22 KOREA Samsung C&T 0.94 KOREA CJ ENM 0.15 KOREA Kakao 3.65 KOREA Samsung Card 0.08 KOREA CJ Logistics 0.12 KOREA Kangwon Land 0.23 KOREA Samsung Electro-Mechanics 0.81 KOREA Coway 0.36 KOREA KB Financial Group 1.78 KOREA Samsung Electronics 25.36 KOREA Daewoo Engineering & Construction 0.12 KOREA KCC Corp 0.12 KOREA Samsung Electronics Pfd.
  • Holdings-Report.Pdf

    Holdings-Report.Pdf

    The Fund is a closed-end exchange traded management Investment company. This material is presented only to provide information and is not intended for trading purposes. Closed-end funds, unlike open-end funds are not continuously offered. After the initial public offering, shares are sold on the open market through a stock exchange. Changes to investment policies, current management fees, and other matters of interest to investors may be found in each closed-end fund's most recent report to shareholders. Holdings are subject to change daily. PORTFOLIO HOLDINGS FOR THE KOREA FUND as of July 31, 2021 *Note: Cash (including for these purposes cash equivalents) is not included. Security Description Shares/Par Value Base Market Value (USD) Percent of Base Market Value SAMSUNG ELECTRONICS CO 793,950 54,183,938.27 20.99 SK HYNIX INC COMMON 197,500 19,316,452.95 7.48 NAVER CORP COMMON STOCK 37,800 14,245,859.60 5.52 LG CHEM LTD COMMON STOCK 15,450 11,309,628.34 4.38 HANA FINANCIAL GROUP INC 225,900 8,533,236.25 3.31 SK INNOVATION CO LTD 38,200 8,402,173.44 3.26 KIA CORP COMMON STOCK 107,000 7,776,744.19 3.01 HYUNDAI MOBIS CO LTD 26,450 6,128,167.79 2.37 HYUNDAI MOTOR CO 66,700 6,030,688.98 2.34 NCSOFT CORP COMMON STOCK 8,100 5,802,564.66 2.25 SAMSUNG BIOLOGICS CO LTD 7,230 5,594,175.18 2.17 KB FINANCIAL GROUP INC 123,000 5,485,677.03 2.13 KAKAO CORP COMMON STOCK 42,700 5,456,987.61 2.11 HUGEL INC COMMON STOCK 24,900 5,169,415.34 2.00 SAMSUNG 29,900 4,990,915.02 1.93 SK TELECOM CO LTD COMMON 17,500 4,579,439.25 1.77 KOREA INVESTMENT 53,100 4,427,115.84
  • Korea Morning Focus

    Korea Morning Focus

    December 23, 2019 Korea Morning Focus No English report summaries this morning Major Indices Close Chg Chg (%) KOSPI 2,204.18 7.62 0.35 KOSPI 200 295.31 1.00 0.34 KOSDAQ 649.73 1.88 0.29 Turnover ('000 shares, Wbn) Volume Value KOSPI 637,639 5,021 KOSPI 200 75,360 3,446 KOSDAQ 929,806 4,198 Market Cap (Wbn) Value KOSPI 1,481,267 KOSDAQ 234,817 KOSPI Turnover (Wbn) Buy Sell Net Foreign 2,004 1,848 156 Institutional 986 847 139 Retail 1,961 2,283 -322 KOSDAQ Turnover (Wbn) Buy Sell Net Foreign 518 418 100 Institutional 172 164 8 Retail 3,484 3,568 -84 Program Buy / Sell (Wbn) Buy Sell Net KOSPI 1,813 1,611 203 KOSDAQ 485 406 79 Advances & Declines Advances Declines Unchanged KOSPI 437 366 105 KOSDAQ 609 601 134 KOSPI Top 5 Most Active Stocks by Value (Wbn) Price (W) Chg (W) Value Samsung Electronics 56,000 0 676 Hynix 95,000 1,400 263 KODEX Leverage 14,145 65 183 Jooyon 804 31 161 KODEX Kosdaq150 8,005 85 150 Leverage KOSDAQ Top 5 Most Active Stocks by Value (Wbn) Price (W) Chg (W) Value HLB 102,200 3,300 205 Energy Solutions 25,850 2,750 170 BRIDGE 54,300 -8,100 140 BIOTHERAPEUTICS SyntekaBio 15,100 650 113 ESA 2,060 -635 103 Note: As of December 20, 2019 This document is a summary of a report prepared by Mirae Asset Daewoo Co., Ltd. (“Mirae Asset Daewoo”) and published on our website.
  • Assessment Report on Extension(S) of Marketing Authorisation

    Assessment Report on Extension(S) of Marketing Authorisation

    19 September 2019 EMA/CHMP/548703/2019 Committee for Medicinal Products for Human Use (CHMP) Assessment Report on extension(s) of marketing authorisation Remsima International non-proprietary name: infliximab Procedure No. EMEA/H/C/002576/X/0062 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure ............................................ 11 1.1. Submission of the dossier .................................................................................... 11 1.2. Steps taken for the assessment of the product ....................................................... 11 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.2. About the product .............................................................................................. 13 2.3. Type of Application and aspects on development .................................................... 14 2.4. Quality aspects .................................................................................................
  • Truxima (Rituximab-Abbs) – New and Expanded Indications

    Truxima (Rituximab-Abbs) – New and Expanded Indications

    Truxima® (rituximab-abbs) – New and expanded indications • On May 23, 2019, the FDA approved Teva and Celltrion’s Truxima (rituximab-abbs), for the treatment of adult patients with previously untreated diffuse large B-cell, CD20-positive non-Hodgkin’s lymphoma (NHL) in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens; and with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL) in combination with fludarabine and cyclophosphamide (FC). • Previously, Truxima was approved for the following: — Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent — Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy — Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy. • Truxima is a biosimilar to Genentech and Biogen’s Rituxan® (rituximab). — Rituxan is also approved for the treatment of adult patients with rheumatoid arthritis, granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis, and pemphigus vulgaris. • Similar to Rituxan, Truxima carries a boxed warning for fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. • The most common adverse reactions (≥ 25%) with Truxima use in NHL were infusion-related reactions, fever, lymphopenia, chills, infection and asthenia. • The most common adverse reactions (≥ 25%) with Truxima use in CLL were infusion-related reactions and neutropenia. • The recommended dose of Truxima in the expanded NHL indication is 375 mg/m2 as an intravenous infusion on day 1 of each cycle of chemotherapy, for up to 8 infusions.
  • Truxima Prescribing Information

    Truxima Prescribing Information

    HIGHLIGHTS OF PRESCRIBING INFORMATION TRUXIMA® (rituximab-abbs) injection, for intravenous use These highlights do not include all the information needed to use TRUXIMA safely and effectively. See full prescribing information for TRUXIMA. • The dose for RA in combination with methotrexate is two-1000 mg intravenous infusions separated by 2 weeks (one course) every 24 weeks or based on clinical TRUXIMA® (rituximab-abbs) injection, for intravenous use evaluation, but not sooner than every 16 weeks. Initial U.S. Approval: 2018 Methylprednisolone 100 mg intravenous or equivalent glucocorticoid is recommended TRUXIMA (rituximab-abbs) is biosimilar* to RITUXAN® (rituximab) 30 minutes prior to each infusion (2.5). WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS • The induction dose for adult patients with active GPA and MPA in combination with REACTIONS, HEPATITIS B VIRUS REACTIVATION glucocorticoids is 375 mg/m2 once weekly for 4 weeks. The follow up dose for and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY adult patients with GPA and MPA who have achieved disease control with induction See full prescribing information for complete boxed warning. treatment, in combination with glucocorticoids is two 500 mg intravenous infusions • Fatal infusion-related reactions within 24 hours of rituximab infusion; separated by two weeks, followed by a 500 mg intravenous infusion every 6 months approximately 80% of fatal reactions occurred with first infusion. Monitor thereafter based on clinical evaluation (2.6). patients and discontinue TRUXIMA infusion for severe reactions (5.1). DOSAGE FORMS AND STRENGTHS • Severe mucocutaneous reactions, some with fatal outcomes (5.2). Injection: 100 mg/10 mL (10 mg/mL) and 500 mg/50 mL (10 mg/mL) solution in • Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant single-dose vials (3) hepatitis, hepatic failure, and death (5.3).
  • Voting Disclosure

    Voting Disclosure

    Notices: LGPS Central Limited is committed to disclosing its voting record on a vote-by-vote basis, including where practicable the provision of a rationale for votes cast against management. The data presented here relate to voting decisions for securities held in portfolios held within the company’s Authorised Contractual Scheme (ACS). Meeting Company Name Meeting Type Voting Action Agenda Item Numbers Voting Explanation 20/01/2021 Guotai Junan International Holdings Limited Special All For 04/02/2021 Lenovo Group Limited Special All For 04/03/2021 MMG Ltd. Special Against 1 Apparent failure to link pay and appropriate performance 05/03/2021 CSPC Pharmaceutical Group Ltd. Special Against 11.1 Concerns related to board gender diversity 12 Concerns related to shareholder rights 29/03/2021 China Resources Beer (Holdings) Co. Ltd. Special Against 2 Concerns related to board gender diversity 28/01/2021 Kobe Bussan Co., Ltd. Annual All For 28/01/2021 Park24 Co., Ltd. Annual Against 1.6,1.7 Concerns about overall board structure 19/02/2021 Kansai Mirai Financial Group, Inc. Special All For 20/02/2021 OSG Corp. (6136) Annual Against 2.1 Concerns related to approach to board diversity 25/02/2021 Kewpie Corp. Annual All For 26/02/2021 Hitachi Capital Corp. Special Against 1 Concerns to protect shareholder value 26/02/2021 Mitsubishi HC Capital, Inc. Special All For 09/03/2021 Nippon Building Fund, Inc. Special All For 18/03/2021 Toshiba Corp. Special Against 1 SH: For shareholder resolution, against management recommendation / Shareholder proposal promotes transparency 19/03/2021 Kubota Corp.
  • Approved and Pending Biosimilar Applications* *Based on Publicly

    Approved and Pending Biosimilar Applications* *Based on Publicly

    Approved and Pending Biosimilar Applications* Biosimilar Reference Product Marketing Litigation Status (Active or Pending) Name: Zarxio® Name: Neupogen® Approved by U.S. Supreme Court (filgrastim-sndz) (filgrastim) FDA on opinion issued on March 6, 2015. June 12, 2017. Manufacturer: Sandoz Manufacturer: Amgen Commercial U.S. Court of Appeals BLA: 125553 BLA: 103353 launch by for the Federal Circuit Sandoz/Novartis en banc opinion Indications/Uses: Treats in September issued on neutropenia by increasing 2015. December 14, 2017. production of white blood cells. Often used Litigation in the U.S. for patients taking District Court for the chemotherapy treatments Northern District of or after bone marrow California; summary transplantation. judgment of non- infringement entered on January 1, 2018; on appeal to the U.S. Court of Appeals for the Federal Circuit. Name: Inflectra® Name: Remicade® Approved by Litigation initiated in (infliximab-dyyb) (infliximab) FDA on April 5, the U.S. District Court 2016. for the District of Manufacturer: Celltrion, Manufacturer: Janssen Massachusetts. Inc. Biotech, Inc. Commercial (at- risk) launch by Grant of Celltrion’s BLA: 125544 BLA: 103772 Pfizer/Celltrion motion for summary in November judgment currently on Indications/Uses: 2016. appeal to the U.S. Inhibits tumor necrosis Court of Appeals for factor-alpha to reduce the Federal Circuit. inflammation in patients with the following autoimmune diseases: rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, and ankylosing spondylitis. *Based on publicly available information as of the date of this publication. Last revised December 13, 2018 – FOR INFORMATIONAL PURPOSES ONLY. Approved and Pending Biosimilar Applications* Name: Erelzi® Name: Enbrel® Approved by Litigation in the U.S.
  • Korea Morning Focus

    Korea Morning Focus

    January 30, 2020 Korea Morning Focus Company News & Analysis Major Indices Close Chg Chg (%) Samsung Electro-Mechanics (009150/Buy/TP: W160,000) Raise TP KOSPI 2,185.28 8.56 0.39 A mixed outlook KOSPI 200 293.98 1.21 0.41 KOSDAQ 670.18 5.48 0.82 LG Innotek (011070/Buy/TP: W201,000) Raise TP Positives abound Turnover ('000 shares, Wbn) Volume Value POSCO Chemical (003670/Trading Buy/TP: W70,000) Downgrade rating, KOSPI 681,558 6,590 but raise TP KOSPI 200 84,850 4,457 KOSDAQ 1,040,290 5,574 Expectations of growth driving shares higher Market Cap (Wbn) LG H&H (051900/Buy/TP: W1,640,000) Value China growth on track KOSPI 1,472,172 KOSDAQ 242,426 KOSPI Turnover (Wbn) Buy Sell Net Foreign 1,649 1,548 101 Institutional 1,534 2,032 -498 Retail 3,355 2,982 373 KOSDAQ Turnover (Wbn) Buy Sell Net Foreign 561 599 -38 Institutional 197 206 -9 Retail 4,792 4,713 79 Program Buy / Sell (Wbn) Buy Sell Net KOSPI 1,445 1,467 -21 KOSDAQ 505 571 -66 Advances & Declines Advances Declines Unchanged KOSPI 516 305 88 KOSDAQ 779 450 115 KOSPI Top 5 Most Active Stocks by Value (Wbn) Price (W) Chg (W) Value Samsung Electronics 59,100 300 965 Hynix 97,900 1,600 269 KODEX Leverage 14,355 40 268 KODEX Kosdaq150 8,220 170 208 Leverage KODEX 200 Futures 6,095 -35 174 Inverse 2X KOSDAQ Top 5 Most Active Stocks by Value (Wbn) Price (W) Chg (W) Value Boditech 16,900 0 229 OKONG Corp.
  • CELLTRION Inc. CT-P13 3.5

    CELLTRION Inc. CT-P13 3.5

    CELLTRION Inc. CT-P13 3.5 A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis 24th March 2019 Statistical Analysis Plan Part 2 – Final Version 4.0 Prepared by: XXXXXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXX XXXX XXXXXXX Prepared by: ____________________________ Date: ____/____/____ XXXXXXXXXXXX XXXXXXXX XXXXXXXXXX Approved by: ____________________________ Date: ____/____/____ XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXX Upon review of this document, including table, listing and figure shells, the undersigned approves the final statistical analysis plan. The analysis methods and data presentation are acceptable, and the table, listing and figure production can begin. I Confidential Confidential CELLTRION, Inc. Statistical Analysis Plan, Part 2 – Final Version 4.0 CT-P13 3.5 Date Issued: 24th March 2019 TABLE OF CONTENTS 1. ADMINISTRATIVE STRUCTURE .......................................................................... 6 2. INTRODUCTION........................................................................................................ 6 3. STUDY OBJECTIVE .................................................................................................. 7 3.1. Primary Objective .................................................................................................. 7 3.2. Secondary Objectives............................................................................................
  • Studio Dragon Corporation (253450 KQ ) Mr

    Studio Dragon Corporation (253450 KQ ) Mr

    Studio Dragon Corporation (253450 KQ ) Mr. Sunshine is coming to Netflix Media Netflix deal for Mr. Sunshine worth at least W28.7bn After yesterday’s market close, Studio Dragon announce d in a regulatory filing that it Company Update signed a licensing contract with Netflix for its upcoming drama Mr. Sunshine . While the exact size of the deal (recognized as licensing revenue) was not revealed, we believe the June 22, 2018 deal is worth at least W28.7bn, given disclosure regulations. At the low end, the figure represents more than 70% of the drama’s production costs and a sharp increase from the prices of previous Netflix deals (50% of production costs). Given the rising value of content worldwide, we think it is likely the latest contract is worth more than the low-end figure . (Maintain) Buy Considering that the latest deal does not include China, we could see additional licensing sales once exports to China resume. Following the recent IPO of iQiyi, the battle for content among China’s three biggest OTTs has been intensifying . There is Target Price (12M, W) ▲ 150,000 also significant pent-up demand for Korean content. While the timing is not certain , we see potential for a deal worth over W10bn within the next year. Share Price (06/21/18, W) 116,100 Raising earnings estimates and target price; risks skew to upside Expected Return 29% We expect higher pricing of large-scale content to generate earnings leverage. We believe price gains are the result of: 1) the execution of a content business model (i.e., expanding beyond domestic ad sales to global content rights); 2) t he emergence of OP (18F, Wbn) 67 streaming giants (Netflix, Amazon, etc.); and 3) the scarcity of Korean big-budget Consensus OP (18F, Wbn) 67 content.